Nasal Spray Approved By FDA for Treating Certain Seizures in Patients with Epilepsy
May 20th 2019Left untreated, seizure clusters can increase the risk of physical injury, neurological damage, prolonged seizures, and status epilepticus, according to UCB, and many diagnosed patients with may go untreated when preferred treatment options are unavailable.
Aflibercept for Diabetic Retinopathy Receives FDA Approval
May 14th 2019The PANORAMA trial showed that by 1 year, 20% of untreated patients developed proliferative diabetic eye disease, and aflibercept injection reduced this risk by 85% to 88% when administered using an every 16-week or eight-week dosing regimen, respectively.
Increase of Pediatric Nurse Practitioners Needed to Overcome Shortage
May 7th 2019With approximately 18,100 PNPS and 50,000 primary care pediatricians currently in the workforce, there are insufficient numbers of pediatric primary care providers to care for the increasingly demanding and complex needs of children.
First Vaccine for Prevention of Dengue Disease in Endemic Regions Granted FDA Approval
May 2nd 2019The drug application was granted the FDA’s Priority Review designation, as well as a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases.
FDA Approves Drug to Reduce Risk of Heart Attack
April 29th 2019High levels of ‘bad’ cholesterol, also known as low-density lipoprotein cholesterol (LDL-C), increase patients' risk for serious CV events such as heart attack or stroke. Adults who experience a heart attack or stroke have an approximately 1 in t3 chance to have another CV event.
FDA Approves Pediatric Lupus Treatment
April 26th 2019This is the first time that the FDA has approved a treatment for pediatric patients with SLE. Belimumab has been approved for use in adult patients since 2011. GSK’s application for belimumab use in pediatric patients was granted the FDA’s Priority Review designation.
35 Lots of Bulk Losartan Potassium Tablets Recalled
April 26th 2019This recall was initiated by detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) – found in 6 lots of active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited that is above the FDA’s interim acceptable exposure limit of 9.82 ppm.
Veterans with HIV May Have Higher Risk of Death Associated with Depression
April 19th 2019Investigators from the Boston University School of Medicine (BUSM) used data from participants of the Veteran’s Aging Cohort Study to compare the risk of death among US veterans who were depressed to those not suffering from depression.